GTBP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GT Biopharma Inc (GTBP) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock exhibits bearish technical indicators, lacks positive near-term catalysts, and has weak financial performance. While analysts maintain a 'Buy' rating, the price target has been significantly reduced, and the company's clinical pipeline milestones are years away. Given the user's impatience and preference for long-term investments, this stock does not align well with their goals.
The technical indicators for GTBP are bearish. The MACD is negatively expanding, RSI is neutral at 25.938, and moving averages (SMA_200 > SMA_20 > SMA_5) indicate a downward trend. The stock is trading below its pivot level of 0.38, with key support at 0.357 and resistance at 0.402. The probability of short-term gains is low, with a 50% chance of -0.84% in the next day and only 2.8% in the next month.
The company is advancing its pipeline with Phase 1 trials for GTB-3650 and GTB-5550, targeting hematologic malignancies and solid tumors, respectively. Initial data is expected in 3Q26, and the company has sufficient cash to fund operations through 2026.
Analysts have lowered the price target from $8 to $3, citing increased dilution. There are no recent news events or significant trading trends from hedge funds, insiders, or Congress.
In Q4 2025, the company reported no revenue, a net loss of -$28.9M (up 665.48% YoY), and an EPS of -2.23 (up 33.53% YoY). Gross margin remains at 0%. The financials indicate poor performance with no immediate signs of improvement.
Analysts maintain a 'Buy' rating but have significantly reduced the price target from $8 to $3. This downgrade reflects increased dilution and the long timeline for clinical trial milestones, which may not appeal to impatient investors.
